Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934395 | 0.93 | SLC6A4 (0.50) | MEN1KMT2AKDM4EATMSMN1; SMN2 | |
| SCHEMBL16316305 | 0.87 | SMN1; SMN2 (0.46) | MEN1KMT2AKDM4EATMSMN1; SMN2 | |
| SCHEMBL18159470 | 0.80 | TP53 (0.48) | MEN1KMT2AKDM4EATMSMN1; SMN2 | |
| SCHEMBL576175 | 0.80 | TP53 (0.48) | MEN1KMT2AKDM4EATMSMN1; SMN2 | |
| SCHEMBL775853 | 0.80 | TP53 (0.48) | MEN1KMT2AKDM4EATMSMN1; SMN2 | |
| SCHEMBL13026656 | 0.80 | SLC6A4 (0.56) | MEN1KMT2ASLC6A4MAOASLC6A2 | |
| SCHEMBL6796574 | 0.79 | SLC6A4 (0.53) | MEN1KMT2ASLC6A4MAOASLC6A2 | |
| SCHEMBL16710872 | 0.79 | TP53 (0.42) | MEN1KMT2AKDM4EATMSMN1; SMN2 | |
| SCHEMBL83839 | 0.78 | ALDH1A1 (0.58) | MEN1KMT2ASLC6A4MAOASLC6A2 | |
| SCHEMBL36295 | 0.78 | TP53 (0.67) | ATMSMN1; SMN2CYP1A2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116535339-B | Space conjugated organic molecule based on naphthalene skeleton and preparation and application thereof | 桂林理工大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20240066038-A1 | WNT MODULATORS TO TREAT CENTRAL NERVOUS SYSTEM INJURIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-02-29 | — | — | US | disclosed |
| WO-2023183520-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | A2A PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-116535339-A | Space conjugated organic molecule based on naphthalene skeleton and preparation and application thereof | 桂林理工大学 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-3914458-B1 | SECURITY ELEMENT | BASF SE (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022104113-A1 | SUBSTITUTED MONO- AND POLY-PHENYL-CORE MONOMERS AND POLYMERS THEREOF FOR VOLUME BRAGG GRATINGS | FACEBOOK TECHNOLOGIES, LLC (US) | 2022-05-19 | — | — | WO | disclosed |
| US-7169890-B2 | Process for the production of ramoplanin-like amide derivatives | VICURON PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| WO-2006117548-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1489081-A1 | SPIRO DERIVATIVES AND ADHESION MOLECULE INHIBITORS COMPRISING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-4389413-A | 9,11-Methano-13-aza-11a-carbathrombanoic acid analogues | ONO PHARMACEUTICAL CO. LTD. (JP) | 1983-06-21 | — | — | US | disclosed |
| EP-0044711-A1 | 9,11-Methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-01-27 | — | — | EP | disclosed |
| US-4259330-A | Nematocidal phosphoramidates | ROHM AND HAAS COMPANY (US) | 1981-03-31 | — | — | US | disclosed |
| US-4134993-A | BENZOPHENONE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | MEN1 3349/4885KMT2A 1755/4885KDM4E 1565/4885 |
| US-20060241132-A1 | Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient | VCAM1, SELL, ICAM1 | MEN1 4337/4885KMT2A 2992/4885KDM4E 3531/4885 |
| US-20230015617-A1 | PHTHALAZINONE DERIVATIVES | NR0B1, NR0B2, NR2E1 | MEN1 1419/4885KMT2A 2142/4885KDM4E 3328/4885 |
| US-20240066038-A1 | WNT MODULATORS TO TREAT CENTRAL NERVOUS SYSTEM INJURIES | WNT3A, WNT1, WNT3 | MEN1 3656/4885KMT2A 3514/4885KDM4E 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.